GlassScriptPhysician profile
Shari D Cohen
NPI 1477634764
$7,416.41
in general payments reported to CMS, 2019-2025
46 companies · $1,955 in 2025
The $1,955 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $731 · 2020: $569 · 2021: $1,122 · 2022: $823 · 2023: $968 · 2024: $1,250 · 2025: $1,955.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,109 · Education: $63.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,108.53 |
| Education | $63.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,838.69 | 2020-2025 | Ubrelvy, Qulipta, Vraylar |
| Astrazeneca Pharmaceuticals LP | $947.78 | 2019-2025 | Farxiga, Airsupra |
| Lilly USA, LLC | $801.83 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $425.18 | 2020-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $297.34 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Novo Nordisk INC | $282.24 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astellas Pharma US INC | $230.79 | 2019-2021 | |
| Amgen INC. | $220.24 | 2019-2025 | Repatha, Evenity, Prolia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $206.00 | 2019-2025 | Xifaxan |
| Sumitomo Pharma America, INC. | $192.09 | 2023-2025 | Gemtesa |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $175.57 | 2024-2025 | Caplyta |
| Allergan, INC. | $149.21 | 2020 | |
| Amarin Pharma, INC. | $136.90 | 2021-2022 | |
| Lundbeck LLC | $115.61 | 2023-2025 | Rexulti, Vyepti |
| Merck Sharp & Dohme LLC | $100.68 | 2019-2021 |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shari Cohen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.